Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

PURPOSE: NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile–driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with tumors harboring actionable aberration(s) in fibroblast growth factor receptor (FGFR) 1-3 were treated with AZD4547, an o...

詳細記述

保存先:
書誌詳細
出版年:J Clin Oncol
主要な著者: Chae, Young K., Hong, Fangxin, Vaklavas, Christos, Cheng, Heather H., Hammerman, Peter, Mitchell, Edith P., Zwiebel, James A., Ivy, S. Percy, Gray, Robert J., Li, Shuli, McShane, Lisa M., Rubinstein, Larry V., Patton, David, Williams, P. Mickey, Hamilton, Stanley R., Mansfield, Aaron, Conley, Barbara A., Arteaga, Carlos L., Harris, Lyndsay N., O’Dwyer, Peter J., Chen, Alice P., Flaherty, Keith T.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2020
主題:
ORIGINAL REPORTS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7367548/
https://ncbi.nlm.nih.gov/pubmed/32463741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02630
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料